Thibault Voron

Thibault Voron

Auto-generated profile, based on publicly available information

Thibault Voron

Department of General and Digestive Surgery, Sorbonne Université, Saint-Antoine Hospital, AP-HP, Hopital Saint-Antoine, Paris, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Annals of Surgery
Verified
Journal Article
Closed access
TVThibault Voron
Thibault Voron
LTLambros Tselikas
Lambros Tselikas
DPDaniel Pietrasz
Daniel Pietrasz
FPFrederic Pigneur
Frederic Pigneur
ALAlexis Laurent
Alexis Laurent
DADaniel Azoulay
Daniel Azoulay
Objective: To evaluate the prevalence of sarcopenia among European patients with resectable hepatocellular carcinoma (HCC) and to assess its prognostic impact on overall and disease-free survival. Background: Identification of preoperative prognostic factors in liver surgery for HCC is required to better select patients and improve survival. Recent studies have shown that preoperative discrimination of patients with low skeletal muscle mass (sarcopenic patients) using computed tomography was associated with morbidity and mortality after liver and colorectal surgery. Assessment of sarcopenia could be used to evaluate patients before hepatectomy for HCC. Methods: All consecutive patients who underwent hepatectomy for HCC in our institution, between February 2006 and September 2012, were included. Univariate and multivariate analyses evaluating prognostic factors of postoperative mortality and cancer recurrence were performed, including preoperative, surgical, and histopathological factors. Results: Among 198 patients who underwent hepatectomy for HCC, 109 patients had an available computed tomographic scan and represent the study cohort. After a median follow-up of 21.23 months, 27 patients (24.8%) died. There were 20 deaths among the 59 patients who had sarcopenia and only 7 deaths in the nonsarcopenic group. Sarcopenic patients had significantly shorter median overall survival than nonsarcopenic patients (52.3 months vs 70.3 months; P = 0.015). On multivariate analysis, sarcopenia was found to be an independent predictor of poor overall survival (hazard ratio = 3.19; P = 0.013) and disease-free survival (hazard ratio = 2.60; P = 0.001). Conclusions: Sarcopenia was found to be a strong and independent prognostic factor for mortality after hepatectomy for HCC in European patients and could be used to evaluate eligibility of patients with HCC before surgery.

2 April 2019 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
OGOn behalf of the AFC (French Surgical Association) Working Group
On behalf of the AFC (French Surgical Association) Working Group
DMDiane Mege
Diane Mege
GMGilles Manceau
Gilles Manceau
LBLaura Beyer
Laura Beyer
VBValérie Bridoux
Valérie Bridoux
MKMehdi Karoui
Mehdi Karoui

1 September 2019 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
OGOn behalf of the AFC (French Surgical Association) Working Group
On behalf of the AFC (French Surgical Association) Working Group
GMGilles Manceau
Gilles Manceau
TVThibault Voron
Thibault Voron
DMDiane Mege
Diane Mege
VBValérie Bridoux
Valérie Bridoux
MKMehdi Karoui
Mehdi Karoui

1 January 2015 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MGMartino Guenzi
Martino Guenzi
GAGustavo Arman
Gustavo Arman
CRCédric Rau
Cédric Rau
CCCristiana Cordun
Cristiana Cordun
DMDavid Moszkowicz
David Moszkowicz
JCJean-Marc Chevallier
Jean-Marc Chevallier

3 August 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
TVThibault Voron
Thibault Voron
MBMatthieu Bruzzi
Matthieu Bruzzi
EREmilia Ragot
Emilia Ragot
FZFranck Zinzindohoue
Franck Zinzindohoue
JCJean-Marc Chevallier
Jean-Marc Chevallier
ABAnne Berger
Anne Berger

18 December 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
OCOriana Ciacio
Oriana Ciacio
TVThibault Voron
Thibault Voron
GPGabriella Pittau
Gabriella Pittau
MLMaité Lewin
Maité Lewin
EVEric Vibert
Eric Vibert
DCDenis Castaing
Denis Castaing
Malnutrition is an independent risk factor of postoperative morbidity and mortality and it’s observed in 20 to 50% of surgical patients. Preoperative interventions to optimize the nutritional status, reduce postoperative complications and enteral nutrition has proven to be superior to the parenteral one. Moreover, regardless of the nutritional status of the patient, surgery impairs the immunological response, thus increasing the risk of postoperative sepsis. Immunonutrition has been developed to improve the immunometabolic host response in perioperative period and it has been proven to reduce significantly postoperative infectious complications and length of hospital stay in patients undergoing elective gastrointestinal surgery for tumors. We hypothesize that a preoperative oral immunonutrition (ORAL IMPACT®) can reduce postoperative morbidity in liver resection for cancer. Prospective multicenter randomized placebo-controlled double-blind phase IV trial with two parallel treatment groups receiving either study product (ORAL IMPACT®) or control supplement (isocaloric isonitrogenous supplement - IMPACT CONTROL®) for 7 days before liver resection for cancer. A total of 400 patients will be enrolled. Patients will be stratified according to the type of hepatectomy, the presence of chronic liver disease and the investigator center. The main end-point is to evaluate in intention-to-treat analysis the overall 30-day morbidity. Secondary end-points are to assess the 30-day infectious and non-infectious morbidity, length of antibiotic treatment and hospital stay, modifications on total food intake, compliance to treatment, side-effects of immunonutrition, impact on liver regeneration and sarcopenia, and to perform a medico-economic analysis. The overall morbidity rate after liver resection is 22% to 42%. Infectious post-operative complications (12% to 23%) increase the length of hospital stay and costs and are responsible for a quarter of 30-day mortality. Various methods have been advocated to decrease the rate of postoperative complications but there is no evidence to support or refute the use of any treatment and further trials are required. The effects of preoperative oral immunonutrition in non-cirrhotic patients undergoing liver resection for cancer are unknown. The present trial is designed to evaluate whether the administration of a short-term preoperative oral immunonutrition can reduce postoperative morbidity in non-cirrhotic patients undergoing liver resection for cancer. Clinicaltrial.gov: NCT02041871 .